Sitagliptin attenuated brain damage and cognitive impairment in mice with chronic cerebral hypo-perfusion through suppressing oxidative stress and inflammatory reaction

Journal of Hypertension

Volumn 33, Issue 5, 2015, Pages 1001-1013

  Tsaia, Tzu Hsien ^a   Sun, Cheuk Kwan ^a   Su, Chai Hao ^b   Sung, Pei Hsun ^a   Chua, Sarah ^a   Zhen, Yen Yi ^a   Leu, Steve ^b   Chang, Hsueh Wen ^b   Yang, Jenq Lin ^b   Yip, Hon Kan ^a,b,c  

^a I SHOU UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chronic cerebral hypoperfusion; Oxidative stress inflammation; Sitagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GELATINASE A; GLUCOSE; HISTONE H2AX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; IL10 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BRAIN DAMAGE; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS CALLOSUM; ENZYME ACTIVITY; FRACTIONAL ANISOTROPY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; NOVEL OBJECT RECOGNITION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WHITE MATTER; WHITE MATTER LESION; WORKING MEMORY; ANIMAL; APOPTOSIS; BLOOD; BRAIN; BRAIN ISCHEMIA; C57BL MOUSE; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; DRUG SCREENING; MALE; METABOLISM; RANDOMIZATION;

ANIMALS; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; COGNITION DISORDERS; DRUG EVALUATION, PRECLINICAL; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; RANDOM ALLOCATION; SITAGLIPTIN PHOSPHATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929250349     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000529     Document Type: Article

References (58)

1. Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC. Subcortical ischaemic vascular dementia. Lancet Neurol 2002; 1:426-436.
2. Mascalchi M, Ginestroni A, Toschi N, Poggesi A, Cecchi P, Salvadori E, et al. The burden of microstructural damage modulates cortical activation in elderly subjects with mci and leuko-araiosis. A DTI and fMRI study. Hum Brain Mapp 2014; 35:819-830.
3. Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab 2013; 33:1696-1706.
4. Gorelick PB, Pantoni L. Advances in vascular cognitive impairment. Stroke 2013; 44:307-308.
5. Dong YF, Kataoka K, Toyama K, Sueta D, Koibuchi N, Yamamoto E, et al. Attenuation of brain damage and cognitive impairment by direct renin inhibition in mice with chronic cerebral hypoperfusion. Hypertension 2011; 58:635-642.
6. Pimentel-Coelho PM, Michaud JP, Rivest S. Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiol Aging 2013; 34:679-693.
7. Washida K, Ihara M, Nishio K, Fujita Y, Maki T, Yamada M, et al. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion. Stroke 2010; 41:1798-1806.
8. Sierra C, Domenech M, Camafort M, Coca A. Hypertension and mild cognitive impairment. Curr Hypertens Rep 2012; 14:548-555.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al., Hypertension E-ETFotMoA. 2007 esh-esc practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007; 25:1751-1762.
10. Henskens LH, van Oostenbrugge RJ, Kroon AA, Hofman PA, Lodder J, de Leeuw PW. Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients. J Hypertens 2009; 27:846-853.
11. Rincon F, Wright CB. Vascular cognitive impairment. Curr Opin Neurol 2013; 26:29-36.
12. Scherr M, Trinka E, Mc Coy M, Krenn Y, Staffen W, Kirschner M, et al. Cerebral hypoperfusion during carotid artery stenosis can lead to cognitive deficits that may be independent of white matter lesion load. Curr Neurovasc Res 2012; 9:193-199.
13. Choi BR, Lee SR, Han JS, Woo SK, Kim KM, Choi DH, et al. Synergistic memory impairment through the interaction of chronic cerebral hypoperfusion and amlyloid toxicity in a rat model. Stroke 2011; 42:2595-2604.
14. Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med 2010; 48:1121-1132.
15. Tomimoto H, Ihara M, Wakita H, Ohtani R, Lin JX, Akiguchi I, et al. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol 2003; 106:527-534.
16. Ueno M, Tomimoto H, Akiguchi I, Wakita H, Sakamoto H. Blood-brain barrier disruption in white matter lesions in a rat model of chronic cerebral hypoperfusion. J Cereb Blood Flow Metab 2002; 22:97-104.
17. Zhang W, Smith C, Howlett C, Stanimirovic D. Inflammatory activation of human brain endothelial cells by hypoxic astrocytes in vitro is mediated by il-1beta. J Cereb Blood Flow Metab 2000; 20:967-978.
18. Gu G, Roland B, Tomaselli K, Dolman CS, Lowe C, Heilig JS. Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication. J Comp Neurol 2013; 521:2235-2261.
19. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obesity Relat Metab Disord 2003; 27:313-318.
20. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009; 20:1161-1166.
21. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (glp-1) with the blood-brain barrier. J Mol Neurosci 2002; 18:7-14.
22. Gengler S, McClean PL, McCurtin R, Gault VA, Holscher C. Val(8)glp-1 rescues synaptic plasticity and reduces dense core plaques in app/ps1 mice. Neurobiol Aging 2012; 33:265-276.
23. Salcedo I, Tweedie D, Li Y, Greig NH. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol 2012; 166:1586-1599.
24. Hou J, Manaenko A, Hakon J, Hansen-Schwartz J, Tang J, Zhang JH. Liraglutide, a long-acting glp-1 mimetic, and its metabolite attenuate inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab 2012; 32:2201-2210.
25. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, et al. Ischemiainduced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. J Neurosci Res 2011; 89:1103-1113.
26. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in type 2 diabetic rats. Clin Sci (Lond) 2012; 122:473-483.
27. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368:1696-1705.
28. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, et al. Pharmacokinetics and pharmacodynamic effects of the oral dpp-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46:876-886.
29. Wakita H, Tomimoto H, Akiguchi I, Kimura J. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol 1994; 87:484-492.
30. Shibata M, Ohtani R, Ihara M, Tomimoto H. White matter lesions and glial activation in a novel mouse model of chronic cerebral hypoperfusion. Stroke 2004; 35:2598-2603.
31. Tsai CY, Su CH, Baudrie V, Laude D, Weng JC, Chang AY, et al. Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by mri/dti in a mouse neurogenic hypertension model. Neuro-Image 2013; 82:190-199.
32. Holland PR, Bastin ME, Jansen MA, Merrifield GD, Coltman RB, Scott F, et al. Mri is a sensitive marker of subtle white matter pathology in hypoperfused mice. Neurobiol Aging 2011; 32:2325.
33. Liaury K, Miyaoka T, Tsumori T, Furuya M, Hashioka S, Wake R, et al. Minocycline improves recognition memory and attenuates microglial activation in gunn rat: a possible hyperbilirubinemia-induced animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 50:184-190.
34. Nishio K, Ihara M, Yamasaki N, Kalaria RN, Maki T, Fujita Y, et al. A mouse model characterizing features of vascular dementia with hippocampal atrophy. Stroke 2010; 41:1278-1284.
35. Okamoto Y, Yamamoto T, Kalaria RN, Senzaki H, Maki T, Hase Y, et al. Cerebral hypoperfusion accelerates cerebral amyloid angiopathy and promotes cortical microinfarcts. Acta Neuropathol 2012; 123:381-394.
36. Antunes M, Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn Process 2012; 13:93-110.
37. Carlini VP, Martini AC, Schioth HB, Ruiz RD, Fiol de Cuneo M, de Barioglio SR. Decreased memory for novel object recognition in chronically food-restricted mice is reversed by acute ghrelin administration. Neuroscience 2008; 153:929-934.
38. Masumura M, Hata R, Nagai Y, Sawada T. Oligodendroglial cell death with DNA fragmentation in the white matter under chronic cerebral hypoperfusion: comparison between normotensive and spontaneously hypertensive rats. Neurosci Res 2001; 39:401-412.
39. Love S. Oxidative stress in brain ischemia. Brain Pathol 1999; 9:119-131.
40. Rizk NN, Rafols JA, Dunbar JC. Cerebral ischemia-induced apoptosis and necrosis in normal and diabetic rats: effects of insulin and cpeptide. Brain Res 2006; 1096:204-212.
41. Chen YT, Tsai TH, Yang CC, Sun CK, Chang LT, Chen HH, et al. Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2013; 11:270.
42. Rupprecht LE, Mietlicki-Baase EG, Zimmer DJ, McGrath LE, Olivos DR, Hayes MR. Hindbrain glp-1 receptor-mediated suppression of food intake requires a pi3k-dependent decrease in phosphorylation of membrane-bound akt. Am J Physiol Endocrinol Metab 2013; 305:E751-E759.
43. Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, et al. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) 2013; 35:1621-1636.
44. Briyal S, Gulati K, Gulati A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain Res 2012; 1427:23-34.
45. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab 2011; 31:1696-1705.
46. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, et al. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 2008; 86:326-338.
47. Kim S, Moon M, Park S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J Endocrinol 2009; 202:431-439.
48. Rampersaud N, Harkavyi A, Giordano G, Lever R, Whitton J, Whitton P. Exendin-4 reverts behavioural and neurochemical dysfunction in a premotor rodent model of Parkinson's disease with noradrenergic deficit. Br J Pharmacol 2012; 167:1467-1479.
49. Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement 2014; 10:S47-54.
50. Duffy AM, Holscher C. The incretin analogue d-ala2gip reduces plaque load, astrogliosis and oxidative stress in an app/ps1 mouse model of Alzheimer's disease. Neuroscience 2013; 228:294-300.
51. Irwin N, Gault V, Flatt PR. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease? Expert Opin Invest Drugs 2010; 19:1039-1048.
52. Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest 2013; 4:108-130.
53. Ding KH, Zhong Q, Xie D, Chen HX, Della-Fera MA, Bollag RJ, et al. Effects of glucose-dependent insulinotropic peptide on behavior. Peptides 2006; 27:2750-2755.
54. McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. Cxcl12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol 2006; 177:8053-8064.
55. Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi S, et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007; 204:605-618.
56. Shyu WC, Lin SZ, Yen PS, Su CY, Chen DC, Wang HJ, Li H. Stromal cellderived factor-1 alpha promotes neuroprotection, angiogenesis, and mobilization/homing of bone marrow-derived cells in stroke rats. J Pharmacol Exp Ther 2008; 324:834-849.
57. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. Glp-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. Proc Natl Acad Sci U S A 2009; 106:1285-1290.
58. Lenski M, Kazakov A, Marx N, Bohm M, Laufs U. Effects of dpp-4 inhibition on cardiac metabolism and function in mice. J Mol Cell Cardiol 2011; 51:906-918.